BT INDUSTRY IN SEOULenglish.seoul.go.kr/.../uploads/2016/08/BT-Industry_eng.pdf · 2020-03-30 ·...

BT INDUSTRY IN SEOULSEOUL METROPOLITAN GOVERNMENT

BT In

dustry

Bio

technolo

gy

Invest in Success

INVESTMEN

T

English Edition

BT

IND

UST

RY

IN S

EOU

L

4

Paradigm Shift: Population Aging

The paradigm is globally changing. The largest change is that

the world is witnessing an increase in geriatric diseases such

as osteoporosis, arthritis, degenerative diseases, diabetes, and

hypertension, which causes increase in medical expenses and

thus shortage in the national medical insurance fund. Therefore,

we need more effort in preventing the diseases than in treating

geriatric diseases. In facing these changes, the role of the

biotechnology (BT) industry is becoming larger.

The global biotechnology market is expanding at a double-

digit growth rate thanks to countries focusing their investments

in biotechnology as the national strategic sector. This trend is

expected to last for some time, as is continued growth with

committed investments.

The biopharmaceutical market, which accounts for most of the biotechnology market, is expected to reach USD 189 billion by

2016, growing at a compound annual growth rate (CAGR) of 7.1% from 2009. Global sales from the United States’ and Europe’s antibody

drugs take up 51.7% and 34.8%, respectively, adding up to 86.5% and a majority of the global market. Europe has officially

announced a draft of a guideline on antibody biosimilar products. implying its commercial feasibility, which, in turn, will trigger

global competition for the biosimilar market.

World BT Industry Trend

The BT Industry’s World Market Outlook

Overview of the BT Industry

6,000

5,000

4,000

3,000

2,000

1,000

0 2005

721

3,714

5,179

2010 2015 2020

1,642

17.9%

World market (100M USD) CAGR (%)

12.2%

14.1%

Source: Restructured data from “2020 Vision and Strategy of the Bioindustry.” The Korea Institute for Industrial Economics & Trade

2009 2010 2011 2012 2013

29,075 33,46336,469 40,970

53,549 57,87863,963

71,44575,238

43,574

24,474 24,415 27,46430,475 31,664

SEO

UL

MET

RO

POLI

TAN

GO

VER

NM

ENT

Ove

rvie

w o

f th

e BT

Indu

stry

5

The biotechnology industry is a technology-intensive and high value-added industry, where the R&D cost takes the greater

portion and the acquisition of source technology is critical, and it is one of the next generation growth engines, which many

countries around the world are strategically supporting and promoting.

Korea has also been promoting various policies to develop the BT industry since it enacted the “Biotechnology Support Act”

in 1983. Thanks to active supports from the government and the research & development of biogenerics such as antibiotic

medicines, Korea is equipped with a global competitiveness.

Since the BT market recorded KRW 5,354.9 billion in 2009, it has shown an annual growth rate of 8.9% on average to reach KRW

7,523.8 billion in 2013.

Korea’s BT Industry Market Size by Production (2009–2013)

Korean BT Industry Trend

Domestic sales Export Total of domestic production (Unit: KRW 100 million)

Source: “2013 Statistical Report on the Korean Biotechnology Industry.” The Korea Biotechnology Industry Organization

BT

IND

UST

RY

IN S

EOU

L

4

Paradigm Shift: Population Aging

The paradigm is globally changing. The largest change is that

the world is witnessing an increase in geriatric diseases such

as osteoporosis, arthritis, degenerative diseases, diabetes, and

hypertension, which causes increase in medical expenses and

thus shortage in the national medical insurance fund. Therefore,

we need more effort in preventing the diseases than in treating

geriatric diseases. In facing these changes, the role of the

biotechnology (BT) industry is becoming larger.

The global biotechnology market is expanding at a double-

digit growth rate thanks to countries focusing their investments

in biotechnology as the national strategic sector. This trend is

expected to last for some time, as is continued growth with

committed investments.

The biopharmaceutical market, which accounts for most of the biotechnology market, is expected to reach USD 189 billion by

2016, growing at a compound annual growth rate (CAGR) of 7.1% from 2009. Global sales from the United States’ and Europe’s antibody

drugs take up 51.7% and 34.8%, respectively, adding up to 86.5% and a majority of the global market. Europe has officially

announced a draft of a guideline on antibody biosimilar products. implying its commercial feasibility, which, in turn, will trigger

global competition for the biosimilar market.

World BT Industry Trend

The BT Industry’s World Market Outlook

Overview of the BT Industry

6,000

5,000

4,000

3,000

2,000

1,000

0 2005

721

3,714

5,179

2010 2015 2020

1,642

17.9%

World market (100M USD) CAGR (%)

12.2%

14.1%

Source: Restructured data from “2020 Vision and Strategy of the Bioindustry.” The Korea Institute for Industrial Economics & Trade

2009 2010 2011 2012 2013

29,07533,463 36,469

40,97042,367 47,519

52,081

55,28158,669

43,574

13,292 14,057 15,612 14,311 15,095

BT

IND

UST

RY

IN S

EOU

L

6

The Korean domestic market (domestic sales and import) also has grown from KRW 4,236.7 billion in 2009 to KRW 5,866.9 billion

in 2013, marking a high annual growth rate of 10.7% on average. Also, the BT industry employs as many as 37,778 persons,

making it a major industry in Korea.

Korea’s BT Industry Market Size by Demand (2009–2013)

10 Promising Technologies in the BT Industry

Domestic sales Import Total of domestic demand

Source: “Promising R&D Task Selection from the Viewpoint of Patent.” The Korean Intellectual Property Office. 2013

Promising Technologies

Adult stem cell technology Bio-plastic intermediate manufacturing technology

Cancer bio-marker technology Teleroentgentherapy

Protein stabilization/formulation technology Nano bio-sensor technology

Human antibody manufacturing technology Plant factory artificial lighting technology

Biological CO2/methane conversion technology Hazardous marine life control technology


(Unit: KRW 100 million)

7

Korea’s Biopharmaceutical Market by Sector (2013)

37.6%

Domestic market Export market

Energy and resources

Processing and equipment

Electronics

Environment

Foods

14.6%Electronics

3.7%


1.6%

1.7%

0.8%

0.7%

30.7%Foods

53.1%

Chemicals

10.4%

Pharmaceuticals

Test/inspection, information service, and R&D

Environment

0%

Chemicals

3.5%

Pharmaceuticals

36%


1.3 %3.5%


0.9%

SEO

UL

MET

RO

POLI

TAN

GO

VER

NM

ENT

Ove

rvie

w o

f th

e BT

Indu

stry

Source: “2013 Statistical Report on the Kore an Biotechnology Industry.” The Korea Biotechnology Industry Organization

The pharmaceutical and food fields took 37.6% and 30.7% of

the Korean BT market as of 2013.

Since the separation of the prescribing and dispensing

functions in the medical industry in 2000, drug makers are

commercializing drugs by long-term investment in R&D and

making advance in overseas clinical development through

partnership with foreign drug makers or biotech firms, or

through their own investment, for the purpose of expanding

their share in the global market.

Market Size by Sector

BT

IND

UST

RY

IN S

EOU

L

8

3,048

11,809 10,134

7,686

12,907

9,302

3,6052,449

15,495

13,867

2,216

5,417

10,079

2009 2010 2011 2012 20130

2,000

4,000

6,000

8,000

10,000

12,000

14,000

16,000

18,000

Pharmaceuticals

74.3%


1.7%


1.4%

Electronics

1.6%

Environment

0.9%

Foods

8.9%

Chemicals

8%


3.1%

8,761

11,651

Investment in the BT industry is being actively made, growing from KRW 1,180.9 billion in 2009 to KRW 1,386.7 billion in 2013.

In 2009, investment made in the bio-pharmaceutical sector started to exceed half the total investment in the BT industry, and since

then it has kept growing to reach 74.3% in 2013, recording the highest increase of 28.5% from the previous year.

Korean BT Industry Investment

BT Industry’s Investment Trend for the Recent 5 Years

R&D Expenses by BT Industry Sector

Total CAPEXR&D




10,000

8,000

6,000

4,000

2,000

0PhDs Masters Bachelors Others

2011년 2012년 2013년

1,552 1,637 1,734

5,6725,998 6,201

6,6217,187 7,546

8,260 8,336 8,329

9

As of 2013, 38,197 people worked for 971 biotechnology companies, which showed an increase of 627 people from 2012.

With a steady increase, human resources in the BT industry now consists of 11,605 researchers (30.4%), 12,205 production

personnel (32%), and 14,387 sales/administration personnel (37.7%).

Those in the fields of research and production are the most highly educated—with PhDs (7.3%), masters (26%), and bachelors

(31.7%).

BT Human Resources

(Unit: number of people)

SEO

UL

MET

RO

POLI

TAN

GO

VER

NM

ENT

Ove

rvie

w o

f th

e BT

Indu

stry

BT

IND

UST

RY

IN S

EOU

L

8

3,048

11,809 10,134

7,686

12,907

9,302

3,6052,449

15,495

13,867

2,216

5,417

10,079

2009 2010 2011 2012 20130

2,000

4,000

6,000

8,000

10,000

12,000

14,000

16,000

18,000

Pharmaceuticals

74.3%


1.7%


1.4%

Electronics

1.6%

Environment

0.9%

Foods

8.9%

Chemicals

8%


3.1%

8,761

11,651

Investment in the BT industry is being actively made, growing from KRW 1,180.9 billion in 2009 to KRW 1,386.7 billion in 2013.

In 2009, investment made in the bio-pharmaceutical sector started to exceed half the total investment in the BT industry, and since

then it has kept growing to reach 74.3% in 2013, recording the highest increase of 28.5% from the previous year.

Korean BT Industry Investment

BT Industry’s Investment Trend for the Recent 5 Years

R&D Expenses by BT Industry Sector

Total CAPEXR&D




BT

IND

UST

RY

IN S

EOU

L

10

Korea’s BT Industry by Region

Seoul : 315

Busan : 20

Daegu : 21

Incheon : 17

Gwangju :10

Daejeon : 69

Ulsan : 5

Sejong : 5

Gyeonggi : 250

Gangwon : 56

Chung-buk : 51

Chung-nam : 34

Jeon-buk :18

Gyeong-buk : 34

Gyeong-nam : 28

Jeju : 12

Jeon-nam :26

Seoul : 175

Busan : 16

Daegu : 25

Incheon : 23

Gwangju : 11

Daejeon : 79

Ulsan :8

Sejong : 6

Gyeonggi : 319

Gangwon : 56

Chung-buk :69

Chung-nam : 54

Jeon-buk : 25

Gyeong-buk :36

Gyeong-nam :28

Jeju : 13

Jeon-nam : 28


Number ofHead Offices

Number ofWorkshops

BT Industry in Seoul

As of 2013, there were a total of 971 BT companies in Korea, and

their head offices and workshops were based predominantly in Seoul

and Gyeonggi Province (315 head offices in Seoul and 319 workshops

in Gyeonggi Province). Seoul stands out in some sectors such as

pharmaceuticals, electronics, and information service thanks to its strong

knowledge-based research infrastructure and ICT.

SEO

UL

MET

RO

PO

LITA

N G

OVE

RN

MEN

TO

verv

iew

of

the

BT

Indu

stry

11

Clusters Major Areas (Functions)

① Seoul Magok & Hongneung Clusters Bio and pharmaceutics (R&D)

② Incheon Free Economic Zone Bio and health (R&D/manufacturing)

③ Gyeonggi-do Techno ValleyPharmaceutics and health (R&D/manufacturing)

④ Wonju Medical Devices Cluster Medical devices (R&D/manufacturing)

⑤ Osong Bio ValleyBio, pharmaceutics, and medical devices (R&D)

⑥ Daeduk R&D Special Zone Bio and pharmaceutics (R&D)

⑦ Daegu Medi ValleyPharmaceutics, BT, and medical devices (R&D/manufacturing)

⑧ Jeju Healthcare Town Health (R&D/leisure)

Bioindustry Clusters around the Nation

12

3

4

5

6

7

8

BT

IND

UST

RY

IN S

EOU

L

Hospital Main Area

Asan Medical Center

Parexel, the world’s biggest CRO, selected Asan Medical Center as its first

partner in Asia to collaborate, so that they entered into a collaboration to build a

global clinical trial research system (Feb. 2012)

Samsung Medical

Center

It is Samsung’s platform for BT. At Samsung Medical Center, the Comprehensive

Samsung Cancer Center was established in 2008, and the Samsung Cancer

Research Institute opened with an investment of USD 22 million to conduct

basic studies and clinical trials for new drug development.

Seoul National University

Hospital

Having formed a consortium with SK Telecom, the hospital entered into an

export agreement on its hospital information system and a framework accord

for establishing a joint venture with the Ministry of National Guard, Saudi Arabia

to export its medical information system.

Yonsei University

Severance Hospital

The hospital has entered into an agreement with Softcen and HP Autonomy to

build a medical big data analysis system, and is promoting the establishment of

a joint medical biotechnology cluster at Kazakhstan National University.

12

No 1 City in Clinical Test Competitiveness

Home to the nation’s top 5 hospitals and university hospitals

Home to the nation’s top 5 hospitals and university hospitals, Seoul is emerging as a

world top city for clinical trial (Korea ranked the 10th in the world) and is becoming a

mecca of clinical test.

The factors that make Seoul stand out in the global clinical trial market includes the

state-of-the-art medical devices, outstanding medical research groups with good

communication skills through their experiences of studying in English-speaking

countries, world-class big hospitals providing quality patient administration services,

cost competitiveness, and high potential for entry into emerging markets, to name

a few. In addition, medical service systems such as the national health insurance

service are well established.

The top 5 global medical complexes in Seoul (Asan Medical Center, Samsung

Medical Center, Seoul National University Hospital, Yonsei University Severance

Hospital, and Catholic University Hospital) are not only performing clinical trials on

biomedicines but also endeavoring to facilitate technology transfer and business

startup through their own technology development and technology presentations.

Seoul’s Competitiveness in the BT Industry

City of Clinical Trials NIH, 2012

1

Seoul’s Representative Clinical Trial Hospitals

SEO

UL

MET

RO

PO

LITA

N G

OVE

RN

MEN

TO

verv

iew

of

the

BT

Indu

stry

13

Center of Private Capital Investment

Venture Capitals and Biotechnology Business Investment

Over 90% of venture capital firms (102 firms with USD 1.4 trillion of capital stock paid-up) have their head offices in Seoul, and their

investment in companies in Seoul and Gyeonggi Province account for 73.8% of the total investment (40.3% for those in Seoul and

28.8% for those in Gyeonggi Province), showing that their investments are focused around Seoul and the neighboring metropolitan

area.

The biotechnology sector shows a steady increase in the share of the total investment from 7.7% in 2010 to 10.6% in 2013. In the

biomedical sector, USD 130 million was invested in 63 companies in 2013 and USD 68 million has been invested in 28 companies

as of April 2014.

Foundation of Korea’s First Invention Capital Operation Company for the Protection and Utilization of Patented Technologies

For the purpose of commercializing creative ideas

and inventions, the Korea Institute for Advancement of

Technology (KIAT) and leading companies in Korea

established an invention capital operation company

Intellectual Discovery in 2010 with a capital of KRW

57 billion, which has raised an invention capital up to

KRW 364.5 billion and procured 5,000 patents as of

January 2014.

Others

1.4%Recycling/environmental restoration

1.8%

Information & communications

35.2%

General manufacturing

22.5%Cultural content

20.6%

Biotechnology

10.6%

Service/education

4.3%Logistics

3.6%

Source: Statistics compiled by the Korean Venture Capital Association

Trend of Major Investments in 2013 Based on Items/Amount

BT

IND

UST

RY

IN S

EOU

L

Hospital Main Area

Asan Medical Center

Parexel, the world’s biggest CRO, selected Asan Medical Center as its first

partner in Asia to collaborate, so that they entered into a collaboration to build a

global clinical trial research system (Feb. 2012)

Samsung Medical

Center

It is Samsung’s platform for BT. At Samsung Medical Center, the Comprehensive

Samsung Cancer Center was established in 2008, and the Samsung Cancer

Research Institute opened with an investment of USD 22 million to conduct

basic studies and clinical trials for new drug development.

Seoul National University

Hospital

Having formed a consortium with SK Telecom, the hospital entered into an

export agreement on its hospital information system and a framework accord

for establishing a joint venture with the Ministry of National Guard, Saudi Arabia

to export its medical information system.

Yonsei University

Severance Hospital

The hospital has entered into an agreement with Softcen and HP Autonomy to

build a medical big data analysis system, and is promoting the establishment of

a joint medical biotechnology cluster at Kazakhstan National University.

12

No 1 City in Clinical Test Competitiveness

Home to the nation’s top 5 hospitals and university hospitals

Home to the nation’s top 5 hospitals and university hospitals, Seoul is emerging as a

world top city for clinical trial (Korea ranked the 10th in the world) and is becoming a

mecca of clinical test.

The factors that make Seoul stand out in the global clinical trial market includes the

state-of-the-art medical devices, outstanding medical research groups with good

communication skills through their experiences of studying in English-speaking

countries, world-class big hospitals providing quality patient administration services,

cost competitiveness, and high potential for entry into emerging markets, to name

a few. In addition, medical service systems such as the national health insurance

service are well established.

The top 5 global medical complexes in Seoul (Asan Medical Center, Samsung

Medical Center, Seoul National University Hospital, Yonsei University Severance

Hospital, and Catholic University Hospital) are not only performing clinical trials on

biomedicines but also endeavoring to facilitate technology transfer and business

startup through their own technology development and technology presentations.

Seoul’s Competitiveness in the BT Industry

City of Clinical Trials NIH, 2012

1

Seoul’s Representative Clinical Trial Hospitals

BT

IND

UST

RY

IN S

EOU

L

14

Active Investment Fund Support of the Government

Korea-Seoul Life Science Fund (KSLSF)

The Seoul Government organized and is operating a fund of USD 67 million for the purpose of raising world-class

biotechnology companies that have global competitiveness. Using this fund, the Seoul Government is making efforts

in attracting leading firms and laboratories from Massachusetts, US, as well as in promoting technological information

exchange and commercialization. Invested enterprises at present are as listed below. The Seoul Government will

continue finding and raising promising venture businesses. (GP: Hanhwa Investment, Operon Ventures KSLSF in Boston,

US)

Global Pharmaceutical Industry Promotion Fund

The Ministry of Health and Welfare and the Korea Finance Corporation are operating a USD 89 million-worth fund

to help Korean pharmaceutical companies access the global market. Invested enterprises at present are as listed

below. The Seoul Government will continue finding and raising promising biomedical businesses. (GP: Intervest)

Investment by Biomedical Funds

Company Business Company Business

Kang Stem Holdings Stem Cell Medicine Corestem Stem Cell Medicine

Earlogic Korea Hearing Diagnostic Eubiologics Cholera vaccine development

Crystal Genomics Inc. New Drug Development Chun Lab Genomic analysis

PCL Inc. Vitro Diagnostic Reagent DNP Biotech Gene diagnosis

Pathway Genomics Personal genetic reports Zamat Medical Filter syringe

Pharmapcine Antibody New Drug Phyto Corporation Phyto-natrium

Company Business

Genexine Cervical pre-cancer DNA vaccine

Dinona Immunodepressive therapeutic antibody

Crystal Genomix Next generation medicine for arthritis

SEO

UL

MET

RO

PO

LITA

N G

OVE

RN

MEN

TO

verv

iew

of

the

BT

Indu

stry

15

Active Support of R&D by Businesses

Korea Drug Development Fund (KDDF)

This fund runs USD 1 bil l ion to suppor t the

development of global new drugs in collaboration

among the Ministry of Science, ICT, and Future

Planning, Ministry of Trade, Industry and Energy,

and Ministry of Health and Welfare. Of the projects it

supports, the tuberculosis drug of Qurient succeeded

in licensing out with a Russia state-run fund. Until

now, KDDF has been supporting a total of 40

projects, which are for R&D on anti-cancer drugs,

heart diseases, metabolic diseases, and so on.

Foundation and Operation of Technology Holding Companies at Universities in Seoul

Over 50% of technology holding companies have

been founded at universities in Seoul and are

performing technology transfer and commercialization

using the technologies developed by those

universities. This creates a good environment for

securing technologies owned by the universities.

MetropolitanRegion(17)

DaegyeongRegion

(3)

DongnamRegion

(3)

Jeju Region(1)

GangwonRegion

(1)

ChungcheongRegion

(2)

HonamRegion

(4)

Number of Technology Holding Companies

BT

IND

UST

RY

IN S

EOU

L

16

Creating an Environment for Attracting Global Pharmaceutical Companies

Partnerships betweenMultinational andLocal Companies

Biogen, US – Samsung Bioepis, Korea

Entered into an agreement for developing and commercializing antibody biosimilars for the treatment of autoimmune diseases.

Pfizer, US – LG Bioscience, Korea

Entered into a partnershipfor joint investment and

distribution of generic items.

Johnson & Johnson, US – The Ministryof Health and Welfare, Korea

Clinical R&D investmentfor serious disease infections

Sanofi, France – Asan Medical Center, Korea

Sharing of clinical data of hepatoma patients and co-production of genom data

Merck, Germany – Genexin, Korea

Opened a biotechnology research center.

Novartis, Switzerland – PharmaAbcine, Korea

Novartis, the world’s leading enterprise in the bioscience industry, made an investment in PharmAbcine, a Korean biotechnology venture.

Partnerships between Multinational and Local Companies

Novartis

Merck

MSD

Sanofi

Entered the Korean market in 1984.

Recording a steady, high growth rate as the world’s number 4 pharmaceutical company.Competitive in pharmaceuticals, vaccines, generic drugs (Sandos), etc.


Leading the biopharmaceuticals and chemicals industries with its innovative, advanced technology for the highest quality.Merck Group in Korea consists of Merck Ltd., registered in 1989, and Merck Advanced Technologies Ltd., established in 2002


Strengthened its organization by merger of Merck (the head office of MSD Korea) with Schering-Plough in 2009.Developing innovative pharmaceuticals, vaccines, biotherapeutics, etc.


Growing based on its six key items: emerging markets, vaccines, consumer heal thcare, diabetes, drugs and medical supplies, and veterinary drugs.

BT IN

DUST

RY IN

SEO

UL

SEO

UL

MET

RO

PO

LITA

N G

OVE

RN

MEN

TO

verv

iew

of

the

BT

Indu

stry

17

Conglomerates Expanding into the BT industry

(SK)U-health care

Asan Medical Center

Video-aided robot system(for abdominal and chest insertion

with reduced radiation,increased surgery precision)

LG

Antibodies and new drugs

Hanwha

Antibody biosimilars and new drugs

KolonDegenerative arthritis cell treatment

(Iljin)Medical devices

ConglomeratesExpanding

into theBT industry

Source: Respective Press Release, Kiwoom Securities Research Center

Diagnostic medical devices and U-healthcare, biosimilars and new drugs, cell-chips and customized anti-cancer drugs, molecular diagnostic devices, new biopharmaceuticals, immune diagnostics & lab on chip, bio informatics

BT

IND

UST

RY

IN S

EOU

L

16

Creating an Environment for Attracting Global Pharmaceutical Companies

Partnerships betweenMultinational andLocal Companies

Biogen, US – Samsung Bioepis, Korea

Entered into an agreement for developing and commercializing antibody biosimilars for the treatment of autoimmune diseases.

Pfizer, US – LG Bioscience, Korea

Entered into a partnershipfor joint investment and

distribution of generic items.

Johnson & Johnson, US – The Ministryof Health and Welfare, Korea

Clinical R&D investmentfor serious disease infections

Sanofi, France – Asan Medical Center, Korea

Sharing of clinical data of hepatoma patients and co-production of genom data

Merck, Germany – Genexin, Korea

Opened a biotechnology research center.

Novartis, Switzerland – PharmaAbcine, Korea

Novartis, the world’s leading enterprise in the bioscience industry, made an investment in PharmAbcine, a Korean biotechnology venture.

Partnerships between Multinational and Local Companies

Novartis

Merck

MSD

Sanofi


Recording a steady, high growth rate as the world’s number 4 pharmaceutical company.Competitive in pharmaceuticals, vaccines, generic drugs (Sandos), etc.


Leading the biopharmaceuticals and chemicals industries with its innovative, advanced technology for the highest quality.Merck Group in Korea consists of Merck Ltd., registered in 1989, and Merck Advanced Technologies Ltd., established in 2002


Strengthened its organization by merger of Merck (the head office of MSD Korea) with Schering-Plough in 2009.Developing innovative pharmaceuticals, vaccines, biotherapeutics, etc.


Growing based on its six key items: emerging markets, vaccines, consumer heal thcare, diabetes, drugs and medical supplies, and veterinary drugs.

BT

IND

UST

RY

IN S

EOU

L

18

Overseas Market Entry by Biotechnology Enterprises in Seoul

• Pharmaceutical companies: Korea Vaccine, Ahngook Pharm., and Yuhan Corporation

• Antibody pharmaceutical developer: AbClon

• Stem cell therapeutic agent developers: Medi-post, Pharmicell, and Maria Biotech

• Vaccine producer: Eyegene (two clinical tests in progress in Europe)

Shinpoong Pharm Co., Ltd.:developing, manufacturing, and distribution of drugs and medical supplies

Seegene:genetic testing

Macrogen:genome analysis

Viromed:develops new biopharmaceuticals

• Together with the LFB, a major state-run biopharmaceutical company of France, Shinpoong

founded a partnership company for production of biopharmaceuticals using genetically modified

animals and transfered the protein pharmaceuticals purification technology and the facility-related

technology.

• Shinpoong is planning to export materials (purification) for biopharmaceuticals and finished

biopharmaceuticals that meet the standards of cGMP (FDA) and EU GMP(EMA).

• Seegene’s unique and advanced simultaneous multi-testing technology enables testing tens of

pathogens at once to reduce the cost and helps develop a diagnostic reagent customized to the

patient.

• Seegene accesses overseas markets with its 57 distributors around the world.

• Macrogen established Korea’s largest analysis system and a gene database of 3.5 terabytes or

larger to improve understanding and usability of human genome data.

• Macrogen founded its branches in US, Japan, and Europe to pursue direct marketing of customized

diagnostic reagents in overseas markets.

• Viromed develops new advanced biopharmaceuticals and new drugs made of natural substances

to treat diseases that were previously incurable or hard to cure, and at present is going under

clinical testing in the US as a developer of genetic pharmaceuticals.

• In 2000, Viromed succeeded in inviting USD 6 millions investment from Takara Shuzo (current

Takara Bio Inc), Japan.

SEO

UL

MET

RO

PO

LITA

N G

OVE

RN

MEN

TO

verv

iew

of

the

BT

Indu

stry

19

In 2013, the government designated the BT industry

as a national core industry and task for realizing a

creative economy, and thus it has involved all the

Ministries to go ahead with expanding its investment,

establishing private funds, fostering human resources,

and raising the efficiency of the infrastructure. This

comprehensive governmental support will advance

R&D competitiveness and scale in the BT industry and

facilitate the industry’s entry into markets.

Government Support

Government Support Policy for the BT Industry

2012

▶ Designation of 43 innovative pharmaceutical companies

• The designated companies were given precedence for joining in national R&D projects,

tax supports, priority for determining the price of medicine, and other incentives to help

them grow into global pharmaceutical companies.

▶ The 2nd two-step biotechnology development plan

• The government planned to raise the investment in the BT industry up to KRW 9 trillion

and 707.7 billion and to grow professional manpower consisting of 73,222 masters and

PhDs by 2016.

2013

▶ A long-term R&D plan for national health involving all the Ministries

• The government integrated bio-health plans set by each Ministry, and expanded its support

and lowered the investment barrier in order to activate private investment.

▶ Global pharmaceutical industry advancement fund

• A plan to establish the first pharmaceutical companies exclusive fund worth KRW 100 million

has been carried out based on an investment of KRW 20 million by the Ministry of Health

and Welfare in 2013.

▶ A process to conduct both medicine approval and medicine price evaluation at the same

time was test-operated.

▶ A long-term support plan to be a top 5 power in the biochemical industry by 2020

• Expanding the investment in the biochemical industry, building a total periodic R&D system,

improving the public institution preferential purchasing system, etc.

BT

IND

UST

RY

IN S

EOU

L

18

Overseas Market Entry by Biotechnology Enterprises in Seoul

• Pharmaceutical companies: Korea Vaccine, Ahngook Pharm., and Yuhan Corporation

• Antibody pharmaceutical developer: AbClon

• Stem cell therapeutic agent developers: Medi-post, Pharmicell, and Maria Biotech

• Vaccine producer: Eyegene (two clinical tests in progress in Europe)

Shinpoong Pharm Co., Ltd.:developing, manufacturing, and distribution of drugs and medical supplies

Seegene:genetic testing

Macrogen:genome analysis

Viromed:develops new biopharmaceuticals

• Together with the LFB, a major state-run biopharmaceutical company of France, Shinpoong

founded a partnership company for production of biopharmaceuticals using genetically modified

animals and transfered the protein pharmaceuticals purification technology and the facility-related

technology.

• Shinpoong is planning to export materials (purification) for biopharmaceuticals and finished

biopharmaceuticals that meet the standards of cGMP (FDA) and EU GMP(EMA).

• Seegene’s unique and advanced simultaneous multi-testing technology enables testing tens of

pathogens at once to reduce the cost and helps develop a diagnostic reagent customized to the

patient.

• Seegene accesses overseas markets with its 57 distributors around the world.

• Macrogen established Korea’s largest analysis system and a gene database of 3.5 terabytes or

larger to improve understanding and usability of human genome data.

• Macrogen founded its branches in US, Japan, and Europe to pursue direct marketing of customized

diagnostic reagents in overseas markets.

• Viromed develops new advanced biopharmaceuticals and new drugs made of natural substances

to treat diseases that were previously incurable or hard to cure, and at present is going under

clinical testing in the US as a developer of genetic pharmaceuticals.

• In 2000, Viromed succeeded in inviting USD 6 millions investment from Takara Shuzo (current

Takara Bio Inc), Japan.

BT

IND

UST

RY

IN S

EOU

L

20

The Seoul Government is executing a long term plan to grow the city into a global economic hub and is developing

the Magok R&D Industrial Cluster and Hongneung Smartaging R&D Cluster to foster the biotechnology industry.

Magok Industrial Complex The Magok Industrial Complex was designated as an advanced convergence technology (ICT, BT, GT, and NT) R&D cluster and

an incubator for new technology-based industries. The priority is given to the R&D of cutting-edge technologies. As of now, LG,

Daewoo Ship Building and Marine Engineering (DSME), Kolon, Access Bio, and other enterprises are located at the complex.

Hongneung Smartaging ClusterThe Korea Technology Venture Foundation provides located businesses with systematic and comprehensive services through KIST

(Korea Institute of Science and Technology). The Hongneung district is home to numerous laboratories and universities and thus has

an optimal environment for supporting venture businesses. These outstanding human, physical, and environmental conditions are all

utilized in breeding venture businesses. This district is under review for building a smart aging cluster in the future.

Establishment of a BT Industrial Infrastructure

Base of BT&GT industriesHongneung Research Complex

Magok Industrial Complex

(Cutting-edge convergence technology R&D cluster)

(Smart aging R&D cluster)

BT INDUSTRY IN SEOULSEOUL METROPOLITAN GOVERNMENT

BT In

dustry

Bio

technolo

gy

Invest in Success

INVESTMEN

T

Investment Promotion Division E-mail [email protected] Tel 82-2-2133-5340 Web http://investseoul.com

English Edition

BT INDUSTRY IN SEOULenglish.seoul.go.kr/.../uploads/2016/08/BT-Industry_eng.pdf · 2020-03-30 ·...

Documents

Transcript of BT INDUSTRY IN SEOULenglish.seoul.go.kr/.../uploads/2016/08/BT-Industry_eng.pdf · 2020-03-30 ·...